Expression of c-MET, EGFR and HER-2 of human gastric adenocarcinoma
10.13315/j.cnki.cjcep.2019.01.002
- VernacularTitle:胃腺癌中c-MET、EGFR和HER-2的表达及其与临床病理特征的分析
- Author:
Lin LI
1
;
Yao FU
;
Hong-Yan WU
;
Jun CHEN
;
Jie-Yu CHEN
;
Qi SUN
;
Xin-Yun XU
;
Yi-Hua WANG
;
Xiang-Shan FAN
Author Information
1. 南京大学医学院附属鼓楼医院病理科
- Keywords:
stomach neoplasm;
adenocarcinoma;
c-MET;
EGFR;
HER-2;
immunohistochemistry
- From:
Chinese Journal of Clinical and Experimental Pathology
2019;35(1):6-10
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To investigate the expression status and their clinical significances of c-MET, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER-2) in gastric adenocarcinoma (GC). Methods Tissue samples from 442 cases of GC in patients who accepted D2/D3 radical gastrectomy with R0 resection were stained by immunohistochemistry against c-MET, EGFR and HER-2.Results Over expression of c-MET, EGFR and HER-2 was identified in 195/442 (44.1％), 47/442 (10.6％) and 152/442 (34.4％) GC patients, respectively. Over expression of cMET was more often identified in GC patients with deeper T (P= 0.016), nerve involvement (P = 0.006) and the Lauren diffuse type (P = 0.029). EGFR in cases with vessel permeation (P = 0.012), and HER-2 in cases of distant metastasis (P =0.031), non-nerve involvement (P = 0.024), the Lauren intestinal type (P < 0.001) and G1/G2 grade (P < 0.001). Conclusion The receptors tyrosine kinase (RTKs) markers of cMET, EGFR and HER-2 might involve in the advance of GC, such as invasion and metastasis. The expression status of them could be used as the risk prediction and even the basis for future personalized therapy, especially for tyrosine kinase inhibitor (TKI) therapy, for GC patients.
